Advanced glycation end products increase transglutaminase activity in primary porcine tenocytes

Journal of Investigative Medicine

Volumn 57, Issue 2, 2009, Pages 460-466

  Rosenthal, Ann K ^a,c   Gohr, Claudia M ^a   Mitton, Elizabeth ^a   Monnier, Vincent ^b   Burner, Todd ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c CLEMENT J ZABLOCKI VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Advanced glycation end products; Diabetes mellitus; Factor XIIIA; Tendinopathy; Transglutaminases

Indexed keywords

6 N CARBOXYMETHYLLYSINE; ADVANCED GLYCATION END PRODUCT; COLLAGEN TYPE 1; DNA; LIPOCORTIN 5; MESSENGER RNA; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE; ANTIOXIDANT; DRUG DERIVATIVE; LYSINE; N(6) CARBOXYMETHYLLYSINE; N(6)-CARBOXYMETHYLLYSINE; TETRAZOLIUM; THIAZOLE DERIVATIVE; THIAZOLYL BLUE;

ANTIOXIDANT ACTIVITY; APOPTOSIS; ARTICLE; BIOMECHANICS; CROSS LINKING; DIABETES MELLITUS; DRUG MECHANISM; ENZYME ACTIVITY; HUMAN; NONHUMAN; ANIMAL; CELL CULTURE; CELL SURVIVAL; DOSE RESPONSE; DRUG EFFECT; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; HINDLIMB; METABOLISM; SWINE; TENDON;

SUS;

ANIMALS; ANTIOXIDANTS; APOPTOSIS; CELL SURVIVAL; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GLYCOSYLATION END PRODUCTS, ADVANCED; LYSINE; RNA, MESSENGER; STIFLE; SWINE; TENDONS; TETRAZOLIUM SALTS; THIAZOLES; TRANSGLUTAMINASES;

EID: 85047684563     PISSN: 17088267     EISSN: None     Source Type: Journal    
DOI: 10.2310/JIM.0b013e3181954ac6     Document Type: Article

References (37)

1. Sukenik S, Weitzman S, Buskila D, et al. Limited joint mobility and other rheumatological manifestations in diabetic patients. Diabete Metab. 1987;13:187-192.
2. Akturk M, Karaahmetoglu S, Kacar M, et al. Thickness of the supraspinatus and biceps tendons in diabetic patients. Diabetes Care. 2002;25:408.
3. Mavrikakis M, Drimis S, Kontoyannis D, et al. Calcific shoulder periarthritis (tendinitis) in adult onset diabetes mellitus: a controlled study. Ann Rheum Dis. 1989;48:211-214.
4. Grant W, Sullivan R, Sonenshine D, et al. Electron microscopic investigation of the effects of diabetes mellitus on the Achilles tendon. J Foot Ankle Surg. 1997;36:272-278.
5. Jim Y, Hsu H, Chang C, et al. Coexistance of calcific tendonitis and rotator cuff tear: an arthrographic study. Skeletal Radiol. 1993;22: 183-185.
6. Moren-Hybbinette I, Moritz U, Schersten B. The clinical picture of the painful diabetic shoulder- natural history, social consequences and analysis of the concomitant hand syndrome. Acta Med Scand. 1987;221:73-82.
7. Vogt B, Schleicher E, Wieland O.ε-amino-lysine-bound glucose in human tissues obtained at autopsy: Increase in diabetes mellitus. Diabetes. 1982;31:1123-1127.
8. Lancaster R, Haut R, DeCamp C. Changes in the mechanical properties of patellar tendon preparations of spontaneously diabetic dogs under long term insulin therapy. J Biomech. 1994;27:1105-1108.
9. Nah S-S, Choi I-Y, Yoo B, et al. Advanced glycation end products increases matrix metalloproteinase-1 -3, and -13, and TNF-alpha in human osteoarthritic chondrocytes. FEBS Lett. 2007;581:1928Y1932.
10. Kislinger T, Fu C, Huber B, et al. N(epsilon)-carboxymethyl)lysine adducts of proteins are ligands for receptors for advanced glycation end products that activate cell signaling pathways and modulate gene expression. J Biol Chem. 1999;274:31740-31749.
11. Alikhani M, Alikhani Z, Boyd C, et al. Advanced glycation end products stimulate osteoblast apoptosis via the MAP kinase and cystolic apoptotic pathways. Bone. 2007;40:345-353.
12. Alikhani Z, Alikhani M, Boyd C, et al. Advanced glycation end products enhance expression of pro-apoptotic genes and stimulate fibroblast apoptosis through cytoplasmic and mitochondrial pathways. J Biol Chem. 2005;280:12087-12095.
13. Lorand L, Graham R. Transglutaminases: crosslinking enzymes with pleiotrophic functions. Nature. 2003;4:140-157.
14. Douthwaite J, Johnson T, Haylor J, et al. Effects of transforming growth factor-beta1 on renal extracellular matrix components and their regulating factors. J Am Soc Nephrol. 1999;10:2109-2119.
15. Aeschlimann D, Mosher D, Paulsson M. Tissue transglutaminase and Factor XIII in cartilage and bone remodeling. Semin Thromb Hemost. 1996;22(5):437-443.
16. Heinkel D, Gohr C, Uzuki M, et al. Transglutaminase contributes to CPPD crystal formation in osteoarthritis. Front Biosci. 2004;9:3257-3261.
17. El Nahas A, Abo-Zenah H, Skill N, et al. Elevated e- (γ- Glutamyl)lysine in human diabetic nephropathy results from increased expression and cellular release of tissue transglutaminase. Nephron Clin Pract. 2004;97:c108-17.
18. Skill N, Johnson T, Coutts I, et al. Inhibition of transglutaminase activity reduces extracellular matrix accumulation induced by high glucose levels in proximal tubular epithelial cells. J Biol Chem. 2004; 279:47754-47762.
19. Nagy L, Thomazy V, Saydak M, et al. The promoter of the mouse tissue transglutaminase gene directs tissue-specific, retinoid-regulated and apoptosis-linked expression. Cell Death Differ. 1997;4:534-547.
20. Lanberti P, Wezeman F. Biologic behavior of an InVitro hydrated collagen-human tenocyte tendon model. Clin Orthop Rel Res. 2002; 397:414-423.
21. Schulze-Tanzil G, Mobasheri A, Clegg P, et al. Cultivation of human tenocytes in high-density culture. Histochem Cell Biol. 2004;122: 219-228.
22. Kertesz G, Bourcier B, Cailla H, et al. Immunoradiometric assay of succinylated corticotropin: an improved method for quantification of ACTH. Clin Chem. 1998;44:78-85.
23. Monnier V, Bautista O, Kenny D, et al. Skin collagen glycation, glyoxidation, and crosslinking are lower in subjects with long-term intensive versus conventional therapy of type I diabetes. Diabetes. 1999;48:870-880.
24. Rosenthal AK, Derfus BA, Henry LA. Transglutaminase activity in aging articular chondrocytes and articular cartilage vesicles. Arthritis Rheum. 1997;40(5):966-970.
25. Lowry O, Rosebrough N, Farr A, et al. Protein measurement with Folin-phenol reagent. J Biol Chem. 1951;193:265-275.
26. D'Argenio G, Calvani M, Della Valle N, et al. Differential expression of multiple transglutaminases in human colon: impaired keratinocyte transglutaminaes expression in ulcerative colitis. Gut. 2005;54: 496-502.
27. Sun Y, Kandel R. Deep zone articular chondrocytes in vitro express genes that show specific changes with mineralization. J Bone Miner Res. 1999;14:1916-1925.
28. van de Merbel N, Mentink C, Wolfenbuttel B. Liquid chromatographic method for the quantitative determination of N-carboxymethyllysine in human plasma proteins. J Chromatogr. 2004;808:163-168.
29. Schleicher E, Wagner E, Nerlich A. Increased accumulation of the glycoxidation product Ne-(carboxymethyl)lysine in human tissues in diabetes and aging. J Clin Invest. 1997;99:457-468.
30. Nakano Y, Al-jallad H, Mousa A, et al. Expression and localization of plasma transglutaminase factor XIIIA in bone. J Histochem Cytochem. 2007;55:675-685.
31. Rosenthal A, Masuda I, Gohr C, et al. The transglutaminase, Factor XIIIA , is present in articular chondrocytes. Osteoarthritis Cartilage. 2001;9:578-581.
32. Lin C-L, Wang F-S, Kuo Y, et al. Ras modulation of superoxide activates ERK-dependent fibronectin expression in diabetes-induced renal injuries. Kidney Int. 2006;69:1593-1600.
33. Groenen P, Seccia M, Smulders R, et al. Exposure of AH-crystallin to hydroxyl radicals enhances the transglutaminase susceptibility of its existing amine-donor and amine acceptor sites. Biochem J. 1993; 293:399-404.
34. Muszbek L, Yee V, Hevessy Z. Blood coagulation factor XIII: structure and function. Thromb Res. 1999;94:271-305.
35. Skill N, Griffin M, El Nahas A, et al. Increases in renal ε -(γ -glutamyl)lysine crosslinks results from compartment-specific changes in tissue transglutaminase in early experimental diabetic nephropathy; Pathologic implications. Lab Invest. 2001;81:705-716.
36. Bernassola F, Federici M, Corazzari M, et al. Role of transglutaminase 2 in glucose tolerance: knockout mice studies and a putative mutation in a MODY patient. FASEB J. 2002;16:1371-1378.
37. Holmes F, Haynes L. Superactivation of transglutaminase type 2 without change in enzyme level occurs during progressive neurodegeneration in the mnd mouse. Neurosci Lett. 1996;213:185-188.